TURBO is a virtual international osteosarcoma tumor board designed to bring together multidisciplinary osteosarcoma experts across the globe to review complex cases and share experience and knowledge.
By bringing the best minds in osteosarcoma together on a regular basis, TURBO will encourage collaboration and discussion among osteosarcoma experts. With TURBO, oncologists worldwide have access to experienced and expert osteosarcoma clinicians, regardless of institution or geography.
Only physicians may participate in TURBO. MIB Agents is pleased to offer this resource at no cost to physicians or their patients.
Led by Matteo Trucco, MD, a pediatric oncologist at Cleveland Clinic, TURBO is designed to help physicians collaborate on difficult cases and share clinical experiences.
Top pediatric cancer institutions represented in past sessions include Children’s Hospital Los Angeles, Dana-Farber Cancer Institute/Boston Children’s Hospital, Lucile Packard Children’s Hospital/Stanford University, MD Anderson, Memorial Sloan Kettering, Nationwide Children’s Hospital, Rainbow Babies and Children’s Hospital, Seattle Children’s Hospital, St. Jude Children’s Research Hospital, UC Davis, UCLA, UCSF, and UPMC Children's Hospital of Pittsburgh.
Meetings are conducted via Zoom. Presenting physicians share de-identified cases with the tumor board. Osteosarcoma experts in the field of pediatric oncology, orthopedic oncology, surgical oncology, radiation oncology, radiology, and pathology review the case and discuss options.
A discussion summary is returned to the presenting physician within two days.
Only physicians may submit a case and participate in TURBO.
If you are a patient or caregiver interested in TURBO, please share this information with your physician and ask them to submit a case on your behalf.
If you are a physician interested in submitting a case, please email firstname.lastname@example.org for details on the case submission format and to reserve a spot on the schedule.
Space is limited as 3-4 cases are discussed in each tumor board meeting. Cases will be prioritized according to patient risk and time sensitivity.
Thank you to our partner OncoLens for powering the TURBO platform.